BACKGROUND/OBJECTIVES: Epidemiologic findings concerning the association between coffee consumption and prostate cancer risk yielded mixed results. We aimed to investigate the association by performing a meta-analysis of all available studies. SUBJECTS/METHODS: We searched PubMed, Web of Science and EMBASE for studies published up to July 2013. We calculated the summary relative risk (RR) and 95% confidence intervals (CIs) for ever, moderate and highest consumption of coffee vs non/lowest consumption. The dose-response relationship was assessed by restricted cubic spline model and multivariate random-effect metaregression. RESULTS: A total of 12 case-control studies and 12 cohort studies with 42 179 cases were selected for final meta-analysis. No significant associations were found among overall analysis. A borderline positive association was found for highest drinkers in five small hospital-based case-control (HCC) studies involving 2278 cases. However, compared with non/lowest drinkers, the summary RRs were 0.92 (95% CI ¼ 0.85-0.99) for ever drinkers, 0.92 (95% CI ¼ 0.85-1.00) for moderate drinkers and 0.83 (95% CI ¼ 0.72-0.96) for highest drinkers from 12 cohort studies, comprising a total of 34 424 cases. An increase in coffee intake of two cups/day was associated with a 7% decreased risk of prostate cancer according to cohort studies. A significant inverse relationship was also found for fatal prostate cancers and high-grade prostate cancers. CONCLUSIONS: Case-control studies especially HCC ones might be prone to selection bias and recall bias that might have contributed to the conflicting results. Therefore, the present meta-analysis suggests a borderline significant inverse association between coffee consumption and prostate cancer risk based on cohort studies.
INTRODUCTION
Prostate cancer is the second most frequently diagnosed cancer and the sixth leading cause of cancer death in men globally. 1 In 2013, prostate cancer alone is expected to account for B28% of all new cancer cases among men of the United States. 2 Coffee, the most common beverage in the Western world, can potentially impact the etiology of cancer of various sites along multiple pathways, ranging from carcinogenesis to cellular apoptosis. A number of epidemiological studies have sought to establish a relationship between coffee consumption and prostate cancer risk in the past three decades but with varying results. Two studies have shown an increased prostate cancer risk among coffee drinkers. 3, 4 However, the reduced risk of prostate cancer in coffee drinkers was observed in several studies. [5] [6] [7] A meta-analysis, 8 including the results of eight case-control studies and four cohort studies, found an overall relative risk (RR) of 1.16 (95% confidence interval (CI) ¼ 1.01-1.33) for highest vs lowest coffee drinkers, but the combination of four cohort studies demonstrated no association (RR ¼ 1.06; 95% CI ¼ 0.83-1.35). Another meta-analysis, 9 combining five cohort studies, showed an inverse association of prostate cancer risk with high coffee intake (RR ¼ 0.79; 95% CI ¼ 0.61-0.98). However, both compared only lowest with highest intakes and neither included all the published studies available at the time of their compilations. Furthermore, many studies were published after the previous meta-analysis. Therefore, we systematically conducted a meta-analysis by combining all available data of both case-control and cohort studies to derive a more precise estimation of this association. Besides, we also performed a dose-response analysis, because categories of coffee consumption differed between studies that might complicate the interpretation of the pooled results across study populations with different categories.
MATERIALS AND METHODS

Search strategy
In order to identify all the previous published studies on coffee consumption and risk of prostate cancer, PubMed, Web of Science and EMBASE were searched with the following keywords: 'coffee' and 'prostate' by two independent investigators (last search update: 7 July 2013). Reference lists were examined manually to further identify potentially relevant studies. All the studies matching the eligible criteria listed below were included in our meta-analysis.
case-control or cohort; and (4) the RR with their 95% CIs were reported (or information to calculate them).
Data extraction
Two investigators extracted the data independently. Discrepancies were adjudicated by the third investigator until consensus was achieved on every item. The following information was abstracted from each included articles: the name of first author, year of publication, country origin, study period, study design, sample size (cases and noncases), the exposure to coffee consumption, the RRs and corresponding 95% CIs for each category of coffee consumption and confounders adjusted for in multivariate analysis, respectively.
Assessment of methodological quality
The methodological quality of the included studies was independently evaluated by two investigators using the Newcastle-Ottawa Scale (NOS). 10 Each study was assessed based on three broad perspectives: selection, comparability and exposure with a score ranging from 0 to 9. A score of X7 indicated that one study was of high quality. Discrepancies were adjudicated through discussion and re-evaluation of the methodology of the study in question.
Statistical methods
All statistical analyses were done with Stata software (Version 12; Stata Corporation, College Station, TX, USA), and all tests were two sided. For a study that provided two OR or RR estimates based on population and cancer controls, we used the estimates derived from the population controls.
11 If a study provided separate OR or RR estimates by age or subtype of the disease, we treated them as different studies. 6, 12 Risk estimates were extracted from each study, and log RRs were weighted by the inverse of their variances to obtain a pooled RR and its 95% CI. For each study, non/lowest drinkers represented the reference category, highest drinkers represented the greatest coffee consumption, moderate drinkers represented in-between coffee consumption and ever drinkers represented both greatest and moderate coffee consumption. First, we compared the risk of prostate cancer in ever coffee drinkers with non/ lowest drinkers. For studies that did not report a risk estimate for ever drinkers, a summary estimate was calculated using reported risk estimate for each coffee consumption category. Second, estimates comparing the highest with the non/lowest coffee consumption were calculated. Third, estimates were also calculated for moderate coffee consumption. A summary estimate was also calculated for studies that did not report a risk estimate for moderate drinkers.
Statistical heterogeneity among studies was assessed with the Q and I 2 statistics; 13 a Po0.1 was considered significant. 14 The fixed-effect model (the Mantel-Haenszel method) 15 was used to access the pooled RRs if the heterogeneity was not significant, otherwise the random-effect model (the DerSimonian and Laird method) 16 was used. Subgroup analyses were performed based on study design (hospital-based case-control (HCC) study, population-based case-control study and cohort study), geographic region (America, Asia and Europe), methodological quality (high (with a score X7) and low (with a score o7)) and subtype of prostate cancer (fatal, local, advanced, high grade (Gleason score 47) and low grade (Gleason score o7) prostate cancer) to explore the source of heterogeneity. Meta-regression 17 was conducted to further explore the heterogeneity quantitatively among the studies (the analysis was based on highest vs non/lowest coffee consumption). Sensitivity analyses were performed to reflect the influence of the individual data on the summary RRs. Publication bias was evaluated using the Begg's funnel plot and Egger's test. 18 A two-stage random-effects dose-response meta-analysis was performed to compute the trend from the correlated log RR estimates across levels of coffee consumption taking into account the between-study heterogeneity. 19 For each study, we calculated the median cups of coffee consumption for each category by assigning the midpoint of upper and lower boundaries in each category as the average consumption. When the highest category was open ended, we assigned the lower end value of the category multiplied by 1.5. We examined a potential nonlinear doseresponse relationship between coffee intake and risk of prostate cancer by modeling coffee levels using restricted cubic splines with three knots at percentiles 25, 50 and 75% of the distribution. 20 A P-value for nonlinearity was calculated by testing the null hypothesis that the coefficient of the second spline is equal to 0.
Studies were not eligible if the required data were not reported or could not be estimated. If coffee consumption was indicated by ml (or g), 21, 22 we defined 250 ml (or 250 g) of coffee equal to 1 cup. If coffee consumption was measured in a times/day (or occasions/day or drinks/day) scale, 11, 23, 24 we assumed the scale equals to cups/day. Figure 1 outlines the search strategy used to obtain relevant literature. A total of 313 titles and abstracts were identified and screened, and 36 studies were reviewed in detail. Six studies associated with benign prostatic hyperplasia were excluded. Three articles were excluded as their subjects were overlapped in other publications. One study was also excluded because it was not case-control or cohort design. After further excluding 2 reviews, 12 cohort studies 6,7,22-31 and 12 case-control studies 3, 5, 11, 12, 21, [32] [33] [34] [35] [36] [37] [38] involving 527 486 participants and 42 179 cases of prostate cancer were selected for meta-analysis. The characteristics of the included studies are shown in Table 1 .
RESULTS
Characteristics of the studies
Supplementary Tables S1 and S2 present the methodological quality of studies included in the final analysis. The NOS results showed that the average score was 5.8 (range 4-8) for case-control studies and 7.5 (range 4-9) for cohort studies, indicating that the methodological quality of cohort studies was generally good.
Evidence synthesis
The pooled RRs of prostate cancer for the ever, moderate and highest coffee drinkers vs non/lowest drinkers are presented in Table 2 . Compared with non/lowest drinkers, the summary RR was 0.98 (95% CI ¼ 0.92-1.03) for ever drinkers, 0.96 (95% CI ¼ 0.90-1.02) for moderate drinkers and 0.94 (95% CI ¼ 0.85-1.05) for highest drinkers. In the subgroup analyses by study design and subtype of prostate cancer, a statistically significant inverse association was observed for ever, moderate and highest coffee consumption in cohort studies (RR ¼ 0. Figure 2 ). No significant associations were found in other subgroups (not all data shown).
We assessed the dose-response relationship between coffee levels and the risk of prostate cancer with 18 studies. [5] [6] [7] 11, 12, [21] [22] [23] [24] [25] [26] [29] [30] [31] [33] [34] [35] 38 Statistically significant departure from linearity was found for all studies (P ¼ 0.04; Figure 3a ), but not for cohort studies (P ¼ 0.07; Figure 3b ) and case-control studies (P ¼ 0.38). A 2 cups/day increment in coffee consumption level conferred an RR of 0.97 (95% CI ¼ 0.94-1.01) for overall result, 0.93 (95% CI ¼ 0.88-0.99) for cohort studies and 1.04 (95% CI ¼ 1.00-1.08) for case-control studies.
Sensitivity analysis and publication bias From the results of the leave-one-out sensitivity analysis, the summary RRs were not materially altered (data not shown). We explored the source of heterogeneity by study design (HCC, population-based case-control and cohort studies), geographic region (America, Asia and Europe) and methodological quality The subgroup was only included in the subgroup analysis by subtype of prostate cancer as its subjects were overlapped in the other two subgroups.
Coffee consumption and prostate cancer risk S Zhong et al (continuous variable) with meta-regression. The results for the highest vs non/lowest coffee consumption revealed that study design (P ¼ 0.04) and methodological quality (P ¼ 0.01) but not geographic region (P ¼ 0.10) contributed to the source of heterogeneity.
Begg's funnel plot and Egger's test were used to assess the publication bias of included studies. The graphical funnel plots for all the three comparisons appeared to be symmetrical (Figure 4) . Then, Egger's test was used to provide statistical evidence of funnel plot symmetry. The results still did not show any evidence of publication bias in the overall meta-analysis for the ever, moderate and highest coffee drinkers vs non/lowest drinkers (t ¼ À 0.30, P ¼ 0.77; t ¼ À 0.96, P ¼ 0.35; and t ¼ 0.83, P ¼ 0.42, respectively).
DISCUSSION
This meta-analysis investigated the association between coffee consumption and prostate cancer risk on the basis of previously published researches involving 527 486 participants and 42 179 cases of prostate cancer. The overall summary results indicated no association of coffee consumption with prostate cancer risk. However, an inverse association between coffee consumption and risk of prostate cancer was observed in cohort studies, whereas no association was observed from case-control studies. Interestingly, the five HCC studies with only 2278 cases showed an increased risk of prostate cancer among highest coffee drinkers ( Figure 2 and Table 2 ). We noted that there were four HCC studies 3, 32, 36, 37 with smallest sample size that was o1000. In addition, a more precise scale (for example, cups/day) was not used to measure the coffee consumption in three HCC studies, 3,36,37 two 3,36 of which only quantified coffee consumption as 'yes' or 'no' (Table 1) . We also noted that the HCC study conducted in China reported an extremely significant result, and the number of coffee consumers in the sample was very low, consisting of 31 cases (13.1%) and 36 controls (7.5%). 3 After removing this study, the significant result of HCC studies disappeared. In the previous meta-analysis by Park et al., 8 case-control and cohort studies also showed different association results (RR ¼ 1.21, 95% CI ¼ 1.03-1.43; and RR ¼ 1.06, 95% CI ¼ 0.83-1.35, respectively). Their conflicting results might be because of the study mentioned above 3 and another study by Gallus et al. 4 that was excluded in present meta-analysis because its subjects were overlapped by a larger study. 32 In the study by Gallus et al., 4 the authors reported an increased risk of prostate cancer for highest coffee consumption with 219 cases and 431 controls. However, the larger study 32 showed no association anymore with 1294 cases and 1451 controls. Case--control studies especially HCC ones give a lower level of evidence than cohort studies and might provide spurious results because of selection bias and recall bias that might have contributed to the conflicting results in the present meta-analysis. In addition to what is mentioned above, we could easily find that the methodological quality of case-control studies was generally lower (Supplementary  Table S1 ). More than half the studies did not use a representative case population, and almost all ascertained the exposure to coffee without blinding to case-control status. Therefore, the results might have suffered from biases, thus contributing to spurious results. Taking account of all the above-mentioned aspects, we concluded that coffee consumption is associated with decreased risk of prostate cancer.
Several studies have explored coffee consumption and incidence of prostate cancer by subtype of the disease. [5] [6] [7] [28] [29] [30] [31] [32] 38 The results from the subgroup analysis showed a strong inverse association between coffee consumption and fatal or high-grade prostate cancer risk, suggesting that coffee may be implicated in preventing progression of prostate cancer. A recent study indicated that higher prediagnostic coffee consumption was associated with a lower risk of prostate cancer recurrence/progression. 39 The authors defined Coffee consumption and prostate cancer risk S Zhong et al recurrence/progression as patients who died of prostate cancer, developed metastasis, received secondary treatment or had a rising prostate-specific antigen. Nevertheless, they evaluated daily coffee consumption (X1 cup/day vs o1 cup/day) in relation to prostate cancer-specific mortality and observed a nonsignificant 23% lower risk, which might be because of the limited sample size. Therefore, additional large prospective studies of the relationship between coffee consumption and prostate cancer outcomes, including recurrence/progression and prostate cancer-specific mortality, are urgently needed to confirm whether coffee intake is beneficial for secondary prevention. Because the categories of coffee consumption differed between studies, which might complicate the interpretation of the pooled results across study populations with different categories, we also performed dose-response analyses. A nonlinear and not significant dose-response association was found between coffee consumption and prostate cancer risk, and a 2 cups/day increment in coffee consumption level was associated with a 0.97-fold reduced prostate cancer risk. When restricted to cohort studies, a linear and significant dose-response association was found, and the risk of prostate cancer was decreased by 7% for every 2 cups/ day increment in coffee consumption.
Numerous investigations in animals and in vitro cell cultures have tried to establish a link between coffee and cancer. Coffee contains a large number of compounds, some of which have been identified as having potentially chemopreventive effects. Caffeine, one of the major components of coffee, could slightly stimulate apoptosis of prostate cancer cells through activating ryanodine receptor. 40 Studies, 7, 31 however, showed that regular and decaffeinated coffee showed no difference on risk of prostate cancer, suggesting that noncaffeine components of coffee may play more important roles in preventing prostate cancer development. Coffee is also a major source of antioxidants that have been indicated to have an inhibitory effect on carcinogenesis of prostate cancer. 41 Coffee has been observed to be associated with increased total testosterone and sex hormone-binding globulin concentrations. 42 Evidences suggested that free testosterone was inversely associated with the risk of advanced prostate cancer, 43 and sex hormone-binding globulin decreased prostate cancer risk in younger men. 44, 45 Coffee has also been observed to increase the level of plasma adiponectin 46 that was associated with decreased prostate cancer risk. 47 A study reported that p53 and bcl-2, two key regulators of apoptosis, were modulated by adiponectin in prostate cancer cells. 48 It has been Figure 2 . Summary relative risks of prostate cancer for highest coffee consumption vs non/lowest coffee consumption. The squares and horizontal lines correspond to the study-specific RR and 95% CIs. The area of the squares reflects the study-specific weight. The diamond represents the pooled RR and 95% CI.
Coffee consumption and prostate cancer risk S Zhong et al shown that serum adiponectin was inversely correlated with serum insulin-like growth factor 1. 49 There were evidences to suggest that elevated blood levels of insulin-like growth factor 1 have been associated with several cancers, most commonly with prostate cancer. 50 Combined with our results, it seems that coffee intervened in prostate cancer development.
The potential limitations of our study should be considered when interpreting the results. First, the possibility of bias and confounding cannot be excluded for all observational studies of diet and disease. Second, our results are likely to be affected by some misclassification of coffee consumption. Coffee exposure is mostly assessed regarding the number of cups of coffee consumed daily or weekly. However, cup size and brew strength may vary considerably. In addition, there can be important differences in the concentration of coffee components, depending on the coffee variety. Third, our search was restricted to published studies, whereas unpublished studies or original data were not searched. Finally, studies included in this meta-analysis were major conducted in Western countries, and hence the results should be extrapolated to other populations with caution.
In conclusion, our data suggest that coffee consumption or an increased coffee consumption may influence the risk of prostate cancer based on the findings of cohort studies. Regarding the significant heterogeneity among included studies, confirmation in further prospective cohort studies with larger sample size, wellcontrolled confounding factors, long enough follow-up time and more accurate assessment of coffee consumption is essential. Coffee consumption and prostate cancer risk S Zhong et al
